AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01229228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Test
Description: 400-mg (2 x 200-mg)
Study NCT01229228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn
Description: single dose
Study NCT01229228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study NCT00268749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycine
Description: 0.8 g/kg/day
Study NCT01037309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC
Description: Subcutaneous injection, once a week, for five weeks
Study NCT01037309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 IV
Description: Intravenous injection, once a week, for five weeks
Study NCT02747940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flunarizine and/or pregabalin
Study NCT01856686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP22042013
Description: This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
Study NCT04885478 — intervention group
Intervention type: OTHER
Intervention: Immune response monitoring , blood samples
Description: In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~* Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~* Covid-19 Symptoms, clinical monitoring
Study NCT01856686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
Study NCT00259753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevasiranib
Study NCT02470078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phagenyx-Catheter, Phagenesis Limited, UK.
Description: Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
Study NCT02470078 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.
Study NCT02684942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study NCT01319318 — intervention group
Intervention type: PROCEDURE
Intervention: Pars Plana Vitrectomy
Description: Pars plana vitrectomy performed in study eye on Day 0.
Study NCT01594905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Tenofovir (MDR group)
Description: Entecavir 1.0mg + Tenofovir 300mg
Study NCT02282007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual NPMP to the participants
Description: The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
Study NCT03276962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (Full dose)
Description: Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
Study NCT02445079 — intervention group
Intervention type: OTHER
Intervention: This is an observational study only
Description: Observational study only
Study NCT02819726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAIT101
Description: 1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
Study NCT02819726 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: 1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
Study NCT02819726 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: 1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
Study NCT02829034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Study NCT02684942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study NCT03276962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (1/5th dose)
Description: Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
Study NCT03276962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: Participants will receive intramuscular injection of rabies vaccine (0.1 ml).
Study NCT00153868 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience \<1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.
Study NCT03775382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Ascorbic acid will be infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline.
Study NCT03775382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
Study NCT03079869 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ferric Citrate
Description: One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
Study NCT00533585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
Study NCT00533585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 By Vein Over 3 Hours on Day 1.
Study NCT00533585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
Study NCT00533585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
Study NCT03874585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group counseling and nicotine replacement
Description: Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
Study NCT03874585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group counseling, nicotine replacement, and text messaging support
Description: Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
Study NCT02120482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined apheresis
Description: Semiselective immunoadsorption combined with membrane filtration
Study NCT00468312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
Study NCT00468312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sprays in each nostril in the morning
Study NCT02125617 — intervention group
Intervention type: DRUG
Intervention: Abiraterone
Description: 1000 mg/day
Study NCT02125617 — intervention group
Intervention type: DRUG
Intervention: Prednisolone
Description: 10 mg/day
Study NCT05799365 — intervention group
Intervention type: OTHER
Intervention: GMFCS-FR Turkish Adaptation
Description: GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
Study NCT02829034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice per day for a total of 26 weeks
Study NCT03211936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP TITRATED
Description: After titrated peep levels, we choice this level of peep for de group (peep titrated)
Study NCT03211936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP TITRATED
Description: After titrated peep levels, we choice this level of peep for de group (peep titrated)
Study NCT03211936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use ultrasound
Description: We make a lung ultrasound after we setup a different level of PEEP
Study NCT03211936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use ultrasound
Description: We make a lung ultrasound after we setup a different level of PEEP
Study NCT03211936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impedance tomography
Description: We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
Study NCT03211936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance tomography
Description: We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
Study NCT03211936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best PEEP for less collapse
Description: After titrated PEEP levels we setup the best PEEP the according of tomography impedance
Study NCT03211936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP 4
Description: We set the peep level after titrated peep = 4 cmH20.
Study NCT02546245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heroes of Knowledge
Description: Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
Study NCT02546245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention/Time Control Game
Description: Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
Study NCT01785589 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronary angiography
Description: A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
Study NCT01100463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream
Description: Twice daily lotion to prevent HFS
Study NCT01100463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% Uracil Cream
Description: Twice daily lotion to prevent HFS
Study NCT01754558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ajust system
Description: The use of Ajust system for stress incontinence
Study NCT02741752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decortication
Description: cortical bone perforation
Study NCT00448630 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Non-interventional study
Study NCT04428060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PERSEUS CPR
Description: Resuscitation based on patient physiology
Study NCT04428060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPR
Description: Resuscitation based on current guidelines
Study NCT04608656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of livestock feeds
Description: Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season
Study NCT04608656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition counselling
Description: Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
Study NCT00003692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic thoracoscopy
Study NCT01754558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT/TVT-O
Description: sling surgery
Study NCT01057212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
Study NCT00003692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-assisted surgery
Study NCT01057212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
Study NCT01267071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: GSK962040 (50 mg, SD, oral)
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and Metformin FDC Placebo
Description: Alogliptin and metformin FDC placebo-matching tablets
Study NCT01267071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B
Description: 14C GSK962040 (100 μg, SD, iv)
Study NCT01070875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Variation of heparin dose
Description: Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
Study NCT01652573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal salmon calcitonin
Description: 400 IU daily in two sprays (one to each nares)
Study NCT01652573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray Placebo
Study NCT01906580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2a
Description: 180ug peg-IFNα-2a, subcutaneous injection per week
Study NCT01070875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Variation of heparin dose
Description: Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
Study NCT03565718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention: Restaurant
Description: Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
Study NCT03565718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention: Standard/Grocery
Description: Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
Study NCT03056846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Study NCT03056846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Combination
Description: A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Study NCT03056846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum
Description: A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Study NCT03056846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum
Description: A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
Study NCT01181921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
Study NCT04621305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
Study NCT04621305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus Remimazolam
Description: Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
Study NCT04621305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Infusion Remimazolam
Description: Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
Study NCT01841749 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: sentinel node biopsy and mastectomy
Description: sentinel node biopsy and mastectomy
Study NCT01906580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg,oral administration every day
Study NCT03179956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Treatment with ribociclib \[600mg\] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
Study NCT02913261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Description: Ruxolitinib was provided as 5 mg tablets for oral use.
Study NCT02913261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
Study NCT02558660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational intervention about an existing SNAP healthy food incentive program
Study NCT02558660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voucher
Description: $10 voucher to spend on produce at farmers markets
Study NCT03574454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Machine Learning (ML)
Description: Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma